1
Participants
Start Date
March 31, 2014
Primary Completion Date
December 31, 2018
Study Completion Date
December 31, 2019
Sandostatin (Octreotide Acetate)
"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~* Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -\> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~* Frequency: every 4 weeks.~* Route of administration: IM injection."
RECRUITING
Asan Medical Center, Seoul
Lead Sponsor
Novartis Korea Ltd.
INDUSTRY
Asan Medical Center
OTHER